Search

MannKind Corp

Cerrado

SectorSanidad

3.84 3.23

Resumen

Variación precio

24h

Actual

Mínimo

3.68

Máximo

3.84

Métricas clave

By Trading Economics

Ingresos

-2.4M

-19M

Ventas

19M

109M

P/B

Media del Sector

140.5

57.002

BPA

-0.06

Margen de beneficios

-17.401

Empleados

591

EBITDA

10M

13M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+122.25% upside

Dividendos

By Acuity

Próximas Ganancias

4 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

90M

1.3B

Apertura anterior

0.61

Cierre anterior

3.84

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

104 / 340 Clasificación en Healthcare

MannKind Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 ago 2026, 19:01 UTC

MannKind Corp's shares are lower Thursday, continuing a five-day decline amid mixed economic signals and no specific news identified to explain the drop.

12 ago 2026, 20:06 UTC

MannKind Corp shares are lower today, continuing a decline since Tuesday's close amid shifting U.S. Treasury yields and broader market uncertainties.

11 ago 2026, 23:46 UTC

MannKind shares are higher in after-market trading, reflecting a slight recovery amid a cautious market ahead of the upcoming consumer price index report.

10 ago 2026, 22:56 UTC

MannKind Corp shares are higher in after-market hours following Monday's close, though no specific news was identified to explain the price movement.

7 ago 2026, 23:01 UTC

MannKind Corp shares declined in after-market trading, reflecting notable weakness despite remaining above the 20-day moving average. No specific news was identified.

6 ago 2026, 22:01 UTC

MannKind Corp shares are lower in after-market trading, reflecting broader market weakness and trading below their 20-day moving average. No specific news was identified.

5 ago 2026, 23:02 UTC

News

MannKind Corp shares declined after-hours following a second-quarter earnings miss, despite reporting revenues of $109.4 million and FDA approvals for new products.

4 ago 2026, 23:26 UTC

MannKind Corp shares are lower in after-market hours, with no specific news identified to explain the price movement. Trading has remained within a narrow range.

3 ago 2026, 22:51 UTC

MannKind Corp shares are higher in after-market trading, reflecting momentum since Monday's close amid falling Brent crude oil prices and positive market sentiment.

31 jul 2026, 23:56 UTC

MannKind Corp shares traded lower in after-market hours, retreating from earlier gains. The stock remains near the lower end of its one-month range.

30 jul 2026, 18:41 UTC

Event
News

Wells Fargo raised MannKind's price target to $14.00, contributing to positive momentum. The company also reported favorable Phase 1b study results today.

29 jul 2026, 19:47 UTC

News
Event

MannKind Corp reported positive results from its Phase 1b INFLO-1 study, but shares are trading lower amid broader market uncertainty ahead of the Fed's decision.

28 jul 2026, 21:01 UTC

News

MannKind Corp will report its second quarter 2026 financial results on August 5, 2026. Shares are trading higher in after-market hours.

27 jul 2026, 22:06 UTC

MannKind Corp shares are higher in after-market trading, despite earlier declines. No specific news was identified to explain the price movement.

24 jul 2026, 21:01 UTC

Event

MannKind Corp shares are rising in after-market trading following FDA approval of Furoscix ReadyFlow™ for treating edema in heart failure and chronic kidney disease.

23 jul 2026, 10:36 UTC

MannKind Corp shares are higher in pre-market trading, continuing an upward trend since Wednesday, despite declines in the broader tech sector.

22 jul 2026, 21:01 UTC

MannKind Corp shares are higher in after-market trading, reflecting a gain since Wednesday's close, despite remaining below the 20-day moving average.

21 jul 2026, 22:11 UTC

MannKind Corp shares rose in after-market trading, reflecting a broader rebound in technology stocks and strong interest in semiconductor and AI investments.

Comparación entre iguales

Cambio de precio

MannKind Corp previsión

Precio Objetivo

By TipRanks

122.25% repunte

Estimación a 12 Meses

Media 8.29 USD  122.25%

Máximo 13 USD

Mínimo 4.75 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para MannKind Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

5

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

104 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
help-icon Live chat